← Back to Search
N/A
Citicoline for Cognitive Performance
Guelph, Canada
N/A
Recruiting
Led By Kathleen Kelley, MD
Research Sponsored by Kirin Holdings Company, Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
male or female, 35-75 years of age
Be between 18 and 65 years old
Must not have
diagnosis of attention deficit hyperactive disorder (ADHD)
female who is pregnant, planning to be pregnant during the study period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-12 weeks
Summary
This trial tests if citicoline, a brain-boosting supplement, can improve attention in healthy men and women by increasing important brain chemicals. Citicoline is a naturally occurring compound that has shown beneficial effects on memory function and behavior in various populations with cognitive impairments.
See full description
Who is the study for?
This trial is for healthy men and women aged 35-75 who feel they have poor attention. They must score well on mental state and depression tests, not be color blind, or pregnant, and can't have ADHD or major illnesses that could interfere with the study.Check my eligibility
What is being tested?
The trial is testing Citicoline (Cognizin®) against a placebo to see if it improves attention in healthy adults. Participants will take either the supplement or a placebo without knowing which one they're getting.See study design
What are the potential side effects?
While Citicoline is generally considered safe, potential side effects may include headache, insomnia, diarrhea, low or high blood pressure, nausea, blurred vision, chest pains, and others.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 35 and 75 years old.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with ADHD.
show original
Select...
I am not pregnant and do not plan to become pregnant during the study.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0-12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Other study objectives
To assess the safety and tolerability of the TP in healthy participants: Reports of Adverse Events
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Cognizin®Active Control1 Intervention
Active ingredients: Citicoline
Group II: PlaceboPlacebo Group1 Intervention
Active ingredients: none
Find a Location
Closest Location:Apex Trials· Guelph, Canada· 286 miles
Who is running the clinical trial?
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.NETWORK
39 Previous Clinical Trials
2,297 Total Patients Enrolled
Kirin Holdings Company, LimitedLead Sponsor
4 Previous Clinical Trials
929 Total Patients Enrolled
Biofortis Clinical Research, Inc.Industry Sponsor
11 Previous Clinical Trials
951 Total Patients Enrolled
Kathleen Kelley, MDPrincipal InvestigatorBiofortis Clinical Research, Inc. Addison, Illinois, United States, 60101
6 Previous Clinical Trials
559 Total Patients Enrolled
Daisuke Fujiwara, PHDStudy ChairKirin Holding Company Ltd. - Institute of Health Sciences